Ask AI
ProCE Banner Activity

A Year in Review: ADCs Targeting TROP-2 in NSCLC

Slideset

In this downloadable slideset, review an expert’s perspective on the clinical implications of emerging data on TROP-2–directed antibody–drug conjugates as monotherapy or in combination with immune checkpoint inhibitors and chemotherapy on NSCLC management.

Released: January 29, 2024

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.